ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD

References

• VogelmeierCFCrinerGJMartinezFJGlobal strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summaryEur Respir J2017493170021428182564
   PubMed Web of Science ®Google Scholar
• WatzHPittaFRochesterCLAn official European Respiratory Society statement on physical activity in COPDEur Respir J20144461521153725359358
   PubMed Web of Science ®Google Scholar
• ShrikrishnaDPatelMTannerRJQuadriceps wasting and physical inactivity in patients with COPDEur Respir J20124051115112222362854
   PubMed Web of Science ®Google Scholar
• WatzHWaschkiBMeyerTMagnussenHPhysical activity in patients with COPDEur Respir J200933226227219010994
   PubMed Web of Science ®Google Scholar
• van RemoortelHHornikxMDemeyerHDaily physical activity in subjects with newly diagnosed COPDThorax2013681096296323604460
   PubMed Web of Science ®Google Scholar
• WaschkiBSpruitMAWatzHPhysical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter studyRespir Med2012106452253022118987
   PubMed Web of Science ®Google Scholar
• Donaire-GonzalezDGimeno-SantosEBalcellsEBenefits of physical activity on COPD hospitalisation depend on intensityEur Respir J20154651281128926206873
   PubMed Web of Science ®Google Scholar
• WaschkiBKirstenAMHolzODisease progression and changes in physical activity in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192329530626020495
   PubMed Web of Science ®Google Scholar
• WaschkiBKirstenAHolzOPhysical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort studyChest2011140233134221273294
   PubMed Web of Science ®Google Scholar
• TroostersTvan der MolenTPolkeyMImproving physical activity in COPD: towards a new paradigmRespir Res20131411524229341
   PubMed Web of Science ®Google Scholar
• RossiAAisanovZAvdeevSMechanisms, assessment and therapeutic implications of lung hyperinflation in COPDRespir Med2015109778580225892293
   PubMed Web of Science ®Google Scholar
• ThomasMDecramerMO’DonnellDENo room to breathe: the importance of lung hyperinflation in COPDPrim Care Respir J201322110111123429861
   PubMedGoogle Scholar
• TroostersTBourbeauJMaltaisFEnhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study designBMJ Open201664e010106
   Web of Science ®Google Scholar
• BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• MaltaisFHamiltonAMarciniukDImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest200512831168117816162703
   PubMed Web of Science ®Google Scholar
• MaltaisFCelliBCasaburiRAclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPDRespir Med2011105458058721183326
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRVinckenWEffect of indacaterol on exercise endurance and lung hyperinflation in COPDRespir Med201110571030103621498063
   PubMed Web of Science ®Google Scholar
• BeehKMWatzHPuente-MaestuLAclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trialBMC Pulm Med201414120925539654
   PubMed Web of Science ®Google Scholar
• WatzHKrippnerFKirstenAMagnussenHVogelmeierCInda-caterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease–a randomized, multicenter, double-blind, placebo-controlled studyBMC Pulm Med20141415825280934
   PubMed Web of Science ®Google Scholar
• WatzHMailänderCBaierMKirstenAEffects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)BMC Pulm Med20161619527301417
   PubMed Web of Science ®Google Scholar
• TroostersTSciurbaFCDecramerMTiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trialNPJ Prim Care Respir Med2014241400324841833
   PubMed Web of Science ®Google Scholar
• DemeyerHLouvarisZFreiAPhysical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trialThorax201772541542328137918
   PubMed Web of Science ®Google Scholar
• WangerJClausenJLCoatesAStandardisation of the measurement of lung volumesEur Respir J200526351152216135736
   PubMed Web of Science ®Google Scholar
• CoatesALPeslinRRodensteinDStocksJMeasurement of lung volumes by plethysmographyEur Respir J1997106141514279192953
   PubMed Web of Science ®Google Scholar
• MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
   PubMed Web of Science ®Google Scholar
• RabinovichRALouvarisZRasteYValidity of physical activity monitors during daily life in patients with COPDEur Respir J20134251205121523397303
   PubMed Web of Science ®Google Scholar
• Gimeno-SantosERasteYDemeyerHPROactive consortiumThe PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary diseaseEur Respir J2015464988100026022965
   PubMed Web of Science ®Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med2014108458459224534204
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRFrithPEffects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPDEur Respir J2017494160134828424359
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• Puente-MaestuLPalangePCasaburiRUse of exercise testing in the evaluation of interventional efficacy: an official ERS statementEur Respir J201647242946026797036
   PubMed Web of Science ®Google Scholar
• MoyMLCollinsRJMartinezCHAn internet-mediated pedometer-based program improves health-related quality-of-life domains and daily step counts in COPD: a randomized controlled trialChest2015148112813725811395
   PubMed Web of Science ®Google Scholar
• MendozaLHortaPEspinozaJPedometers to enhance physical activity in COPD: a randomised controlled trialEur Respir J201545234735425261324
   PubMed Web of Science ®Google Scholar
• BourbeauJLavoieKLSedenoMBehaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementationBMJ Open201664e010109
   Web of Science ®Google Scholar
• DemeyerHBurtinCHornikxMThe minimal important difference in physical activity in patients with COPDPLoS One2016114e015458727124297
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDBalzanoGImprovements in lung diffusion capacity following pulmonary rehabilitation in COPD with and without ventilation inhomogeneityRespiration201692529530727598467
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDDi MarcoFRaccanelliRValentiVCentanniSFaster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized cross-over studyPulm Pharmacol Ther201535424926549785
   PubMed Web of Science ®Google Scholar
• MoyMLMartinezCHKadriRLong-term effects of an internet-mediated pedometer-based walking program for chronic obstructive pulmonary disease: randomized controlled trialJ Med Internet Res2016188e21527502583
   PubMed Web of Science ®Google Scholar